229 related articles for article (PubMed ID: 16289173)
21. Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells.
Rimler A; Lupowitz Z; Zisapel N
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():45-9. PubMed ID: 12019351
[TBL] [Abstract][Full Text] [Related]
22. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
23. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
24. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
25. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor functioned as a suppressor in the prostate cancer cell line PC3 in vitro and in vivo.
Yu SQ; Han BM; Shao Y; Wu JT; Zhao FJ; Liu HT; Sun XW; Tang YQ; Xia SJ
Chin Med J (Engl); 2009 Nov; 122(22):2779-83. PubMed ID: 19951614
[TBL] [Abstract][Full Text] [Related]
28. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
30. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells.
Gravina GL; Festuccia C; Angelucci A; Poletti A; Capuano D; Vicentini C; Motta M; Bologna M
Int J Oncol; 2004 Jul; 25(1):97-104. PubMed ID: 15201994
[TBL] [Abstract][Full Text] [Related]
31. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
32. 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.
Schwartz GG; Wang MH; Zang M; Singh RK; Siegal GP
Cancer Epidemiol Biomarkers Prev; 1997 Sep; 6(9):727-32. PubMed ID: 9298581
[TBL] [Abstract][Full Text] [Related]
33. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097
[TBL] [Abstract][Full Text] [Related]
34. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
35. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
37. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
[TBL] [Abstract][Full Text] [Related]
38. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
39. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
Zhou C; Ling MT; Kin-Wah Lee T; Man K; Wang X; Wong YC
Cancer Lett; 2006 Feb; 233(1):36-47. PubMed ID: 16473668
[TBL] [Abstract][Full Text] [Related]
40. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
